Organogenesis (ORGO) Reports Q2 Loss, Tops Revenue Estimates

Organogenesis (ORGO) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 58.33%. A quarter ago, it was expected that this regenerative medicine company would post a loss of $0.12 per share when it actually produced a loss of $0.16, delivering a surprise of -33.33%.
Over the last fo…

Click here to view the original article.